Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostinex versus Quinagolide for prevention of ovarian hyperstimulation syndrome
IRCT2016053128187N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cabergoline and quinagolide in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Incidence of ovarian hyperstimulation syndrome. Started Dec 2016; status: completed.
02
Drugs
cabergolinequinagolide
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on IRCT2016053128187N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016053128187N1.